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Abstract
Aim: To characterize the longitudinal variability of estimated glomerular filtration rate
(eGFR) in people with type 2 diabetes mellitus (T2DM), including variation between
categories and individuals.
Methods: People with T2DM and sufficient recorded serum creatinine measure-
ments were identified from the Clinical Practice Research Datalink (T2DM diagnosis
from 1 January 2009 to 1 January 2011 with 5 years follow-up); eGFR was calculated
using the CKD-EPI equation.
Results: In total, 7766 individuals were included; 32.8%, 50.2%, 12.4%, 4.0% and
0.6% were in glomerular filtration rate (GFR) categories G1, G2, G3a, G3b and G4,
respectively. Overall, eGFR decreased by 0.44 mL/min/1.73 m2 per year; eGFR
increased by 0.80 mL/min/1.73 m2 between index and year 1, then decreased by
0.75 mL/min/1.73 m2 annually up to year 5. Category G1 showed a steady decline in
eGFR over time; G2, G3a and G3b showed an increase between index and year
1, followed by a decline. Category G4 showed a mean eGFR increase of
1.85 mL/min/1.73 m2 annually. People in categories G3-G4 moved across a greater
number of GFR categories than those in G1 and G2. Individual patients' eGFR
showed a wide range of values (change from baseline at year 5 varied from −80 to
+59 mL/min/1.73 m2).
Conclusion: Overall, eGFR declined over time, although there was considerable varia-
tion between GFR categories and individuals. This highlights the difficulty in prescrib-
ing many glucose-lowering therapies, which require dose adjustment for renal
function. The study also emphasizes the importance of regular monitoring of renal
impairment in people with T2DM.
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1 | INTRODUCTION
Diabetes is a leading cause of chronic kidney disease (CKD)1 and it is
expected that between 40% and 50% of people with type 2 diabetes
mellitus (T2DM) will be affected by CKD in their lifetimes.2–4 How-
ever, only a small number of glucose-lowering therapies can be used
safely in people with renal impairment without requiring a dose
adjustment.5 Therefore, renal function is an important factor to con-
sider when prescribing glucose-lowering medications in people
with T2DM.
Previous research has showed that renal function, as measured by
estimated glomerular filtration rate (eGFR), can vary considerably,
especially among people with diabetes.6–14 These studies have also
suggested that eGFR improvement among people with T2DM is
possible,11 leading to increased complexity when considering optimal
treatment. Published studies have tended to investigate renal varia-
tion at the population or category level, with one such study reporting
eGFR trends in the UK.11 There are no recent studies reporting
patient-level variation in renal function in a T2DM population.
Using primary care clinical records, this study aims to further char-
acterize the longitudinal variability of eGFR in a cohort of people with
T2DM with availability of consistent eGFR measurements over a
period of 5 years to further explore eGFR trends and patterns over a
longer period, including analysis at the individual patient level.
2 | MATERIALS AND METHODS
2.1 | Data source
Patient records were obtained from the UK Clinical Practice Research
Datalink (CPRD), a primary care database that includes data from gen-
eral practices throughout the UK. As of November 2018, the database
contained anonymized data for approximately 10 million people, with
over 1 in 10 practices in the UK contributing data.15 CPRD data have
been used in over 2000 peer-reviewed publications15, and have been
found to be broadly representative of the UK population in terms of
age, sex, ethnicity and body mass index (BMI).16 Medical records are
updated monthly from participating practices, including complete clin-
ical information, pathology tests, anthropometric data, referral and
prescription records. CPRD is linked to Hospital Episode Statistics
(HES), a database containing details of all hospital admissions,
accident and emergency attendances and outpatient appointments, to
improve ethnicity recording for glomerular filtration rate (GFR)
estimation.17
2.2 | Study population
Individuals were identified in CPRD based on their first diagnosis code
of T2DM (codes are reported in the supporting information). Eligibility
criteria included diagnosis of T2DM between 1 January 2009 and
1 January 2011; individuals also had to have a measure of serum cre-
atinine after T2DM diagnosis (index measurement) and at least one
measure of serum creatinine recorded in 5 yearly intervals post-first
serum creatinine after diagnosis. In addition, the following inclusion
criteria were applied: individuals must have at least 12 months' regis-
tration in practice prior to the index date; belong to an “up-to-stan-
dard” practice at the index date; have a record of ethnicity (identified
through HES linkage, or CPRD if unavailable in HES). Individuals with
a history of type 1 diabetes mellitus were excluded from the analysis.
2.3 | Renal function classification
Renal function was measured via eGFR using the Chronic Kidney Dis-
ease Epidemiology Collaboration (CKD-EPI) equation. To estimate
GFR, the CKD-EPI equation requires data for serum creatinine, age,
sex and ethnicity (see equation in the supporting information).18 The
CKD-EPI equation was selected as it is the recommended formula by
the National Institute for Heath and Care Excellence (NICE).19 Individ-
uals were grouped into GFR categories, as adopted by NICE guide-
lines, according to their eGFR at baseline and follow-up.19 These are
the same categories used by the Kidney Disease: Improving Global
Outcomes (KDIGO) CKD Work Group in their international guidelines
for the management of CKD.20
2.4 | Data analysis
This was a retrospective, descriptive study. Individuals were grouped
into the five clinical categories: G1 (>90 mL/min/1.73 m2), G2 (60-89
mL/min/1.73 m2), G3a (45-59 mL/min/1.73 m2), G3b (30-44 mL/min/
1.73 m2) and G4 (15-29 mL/min/1.73 m2) based on their renal function
at baseline and according to each subsequent yearly measurement.
Category G5 (<15 mL/min/1.73 m2) was also considered, but none of
the study population had an eGFR that fitted within this group.
Baseline characteristics, including age at T2DM diagnosis, age at
the index date, BMI, HbA1c, systolic blood pressure, diastolic blood
pressure and eGFR, were compared among individuals included and
excluded from the analysis using Student's t-test. Renal function was
described for each yearly interval based on the last recorded value per
year and compared with baseline using mean values, counts and per-
centages to identify the raw change in eGFR as well as individual cate-
gory changes. The analysis was performed using Stata version 14.
3 | RESULTS
A total of 46 813 people with newly diagnosed T2DM were identi-
fied; of these, 7766 (16.6%) met the study inclusion criteria
(Figure S1). Most of the included population was white (91.7%), with
South Asian, Black, Chinese and other ethnicities accounting for 4.8%,
1.7% and 1.4% of patients, respectively (Table S1). G2 was the most
common GFR category, representing 50.2% (3900/7766) of the study
population at the index date; 2550 (32.8%), 962 (12.4%), 307 (4.0%)
and 47 (0.6%) were in categories G1, G3a, G3b and G4, respectively
(Table S1). No patients were in category G5.
2 SPANOPOULOS ET AL.
Of the 7766 patients included, only a small subset (1037) had a
recorded albumin creatinine ratio (ACR). No patients had severely
increased ACR (A3; >30 mg/mmol); approximately 24% (253/1037)
had moderately increased ACR (A2; 3-30 mg/mmol) and 76%
(784/1037) had normal ACR (A1; <3 mg/mmol).
On average, there were no relevant differences in the baseline
characteristics of those included and excluded from the analysis in
terms of age, BMI, HbA1c, systolic and diastolic blood pressure and
eGFR (Table S1).
3.1 | Trend analysis
On average, the population's eGFR decreased by 0.44 mL/min/
1.73 m2 annually. However, an eGFR increase of 0.80 mL/min/
1.73 m2 was observed between the index measurement and year 1;
this was followed by a steady eGFR decline (Figure 1).
People in the G1 category at baseline presented with a steady
eGFR decline of 1.28 mL/min/1.73 m2 annually; those in categories
G2, G3a and G3b presented with an eGFR increase between index
and year 1, followed by a steady decline; and those in the G4 category
showed an overall increase in eGFR of 1.85 mL/min/1.73 m2 annually
(Figure 2).
3.2 | GFR category transition analysis
At year 5, 21.3% (1651/7766) of individuals had moved to a lower
GFR category and 20% (1042/5216) had moved to a higher GFR cate-
gory (Table 1). Of the 1316 people in category G3a or below at base-
line, 28.3% (373/1316) moved to G2 or above (eGFR
≥60 mL/min/1.73 m2) at year 5.
During follow-up, patients changed GFR categories 1.5 times on
average [standard deviation (SD) 1.6]. Those with reduced renal func-
tion below 60 mL/min/1.73 m2 (G3 and higher categories) changed
GFR categories more often compared with people with eGFR
≥60 mL/min/1.73 m2 (G1 and G2) (Table 2). In particular, people in
categories G1 and G2 changed GFR categories 1.3 times on average
(SD 1.6 and 1.5, respectively), and people in categories G3a, G3b and
G4 changed GFR categories 2.6 (SD 1.7), 2.1 (SD 1.7) and 2.9 (SD 1.9)
times, respectively.
3.3 | Individual patient analysis
At year 1, 55.5% (4312/7766) of the study population had an increase
or no change in their eGFR and 44.5% (3454/7766) had a decrease;
13.6% (1055/7766) of the study population had their eGFR increased
by at least 10 mL/min/1.73 m2. At year 5, 43.3% (3359/7766) of the
study population had an increase or no change in their eGFR and
56.7% (4407/7766) had a decrease; 15.8% (1228/7766) had their
eGFR increased by at least 10 mL/min/1.73 m2 (Figure 3).
3.4 | Sensitivity analyses
An analysis of eGFR trends was performed based on the mean of all
eGFR values per year, rather than the last recorded eGFR measure-
ment. Overall, this analysis showed that the population's eGFR
decreased by 0.45 mL/min/1.73 m2 annually compared with
0.44 mL/min/1.73 m2 in the main analysis. There was also an increase
of 0.65 mL/min/1.73 m2 in the first year, followed by a steady
decline. Trends in the different GFR categories and at the individual
patient level were very similar to those reported in the main analysis
(Table S4 and Figure S3, respectively).
A second sensitivity analysis was conducted, using the Modifica-
tion of Diet in Renal Disease (MDRD) Study equation instead of the
CKD-EPI equation. This analysis also showed a gradual decline in
eGFR in the overall population, although it was slower than that
shown in the main analysis (0.064 mL/min/1.73 m2 annually;
Table S4). Change in renal function in the GFR categories and at the
individual patient level showed the same trends as reported in the
main analysis (Table S4 and Figure S4, respectively).
Finally, we also looked at eGFR trends according to ACR. The
results in both categories (A1 and A2) followed a similar trend to that
observed in the main analysis (Figure S5).
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4 | DISCUSSION
Although around 50% of people with diabetes develop diabetic
nephropathy during their lifetimes,2–4 disease progression can be
improved through early risk factor interventions including glycaemic
control5 and blood pressure management.21 Optimal treatment for
people with T2DM is related to renal clearance as only a few glucose-
lowering therapies can be prescribed without consideration of renal
function. This study showed that, overall, people with T2DM have a
decline in renal function over time; however, there was variation
within clinical categories of renal function and at the individual level.
In particular, people with worse renal function (eGFR <
60 mL/min/1.73 m2) appeared to show the greatest variation, both
from the overall study population and from their baseline eGFR. Indi-
viduals in the highest GFR category (G1) experienced a consistent and
steady decline in renal function over the study period, whereas those
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TABLE 1 Glomerular filtration rate (GFR) category transition analysis at the end of follow-up (year 5)
GFR category at year 5 (ml/min/1.73 m2)
G1 G2 G3a G3b G4 Increase Decrease
2305 (29.7%) 3891 (50.1%) 975 (12.6%) 496 (6.4%) 99 (1.3%)
N % N %
GFR category
at baseline
(ml/min/1.73 m2)
G1 (≥90) 2550 (32.8%) 1726 (67.7%) 763 (29.9%) 41 (1.6%) 17 (0.7%) 3 (0.1%) N/A N/A 824 32.3
G2 (60-89) 3900
(50.2%)
574 (14.7%) 2760 (70.8%) 454 (11.6%) 104 (2.7%) 8 (0.2%) 574 14.7 566 14.5
G3a (45-59) 962 (12.4%) 4 (0.4%) 340 (35.3%) 405 (42.1%) 191 (19.9%) 22 (2.3%) 344 35.8 213 22.1
G3b (30-44) 307 (4.0%) 1 (0.3%) 24 (7.8%) 70 (22.8%) 164 (53.4%) 48 (15.6%) 95 30.9 48 15.6
G4 (15-29) 47 (0.6%) 0 (0.0%) 4 (8.5%) 5 (10.6%) 20 (42.6%) 18 (38.3%) 29 61.7 0 0.0
1042 20.0 1651 21.3
Red squares indicate a change to a lower GFR category, whereas green squares indicate a change to a higher GFR category. Yellow squares indicate no
change in GFR category.
Abbreviations: eGFR, estimated glomerular filtration rate.
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in the G2, G3a and G3b categories showed an increase at year
1 followed by decline; lastly, those in the G4 category showed an
overall improvement over time. Individuals with an eGFR
<60 mL/min/1.73 m2 at baseline (G3a, G3b and G4) changed GFR cat-
egories more often than those in the higher categories. In addition,
around 28% of people with eGFR <60 mL/min/1.73 m2 at baseline
had an increase in their eGFR to ≥60 mL/min/1.73 m2 by year
5. While the change at the overall population level and in some GFR
categories was small, there was a greater and more clinically relevant
variation at the individual level, with around 15% of patients
experiencing an increase of at least 10 mL/min/1.73 m2. At year
5, the difference from baseline eGFR varied from −80 to
+59 mL/min/1.73 m2. This variation highlights the difficulty in making
treatment decisions based on a single eGFR estimate, as well as rein-
forcing the need for regular renal function screening in people with
T2DM. This is in line with current UK guidelines for renal
monitoring.19
This was a retrospective, observational study to describe how
renal function varies over time in a contemporary real-world cohort of
people with T2DM; the aim was not to investigate the cause(s) of var-
iation. A number of variables were not assessed in this study, includ-
ing use of background medication, treatment received for renal
impairment, comorbidities and other lifestyle factors that could affect
individuals' renal function. Differences in background medications, in
particular, could explain some of the variation at category and individ-
ual levels, as this could be expected to be different between individ-
uals and GFR categories. For example, all GFR categories except G1
showed an increase in eGFR between index and year 1. This could be
because of individuals receiving treatments that affect kidney func-
tion [i.e. angiotensin-converting enzyme (ACE) inhibitors] or a result
of modifications in lifestyle factors such as diet, with the effects of
these interventions reducing over time, leading to decline in renal
function between year 1 and year 5.
Although the study was not designed to explain the causes of vari-
ation in renal function, it does highlight the importance of monitoring
individuals' renal function when considering their T2DM treatment. It
also reflects the situation in the real world where individuals' eGFR
can be affected by a number of factors that are not always clear or
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F IGURE 3 Estimated glomerular filtration rate (eGFR) deviation distribution for (A) year 1 and (B) year 5. Individual level variation
represented by line graphs using raw deviation from baseline value for each patient. Each line represents an individual patient's variation from
baseline eGFR value, ordered from largest reduction in eGFR to largest increase in eGFR (n = 7766). For example, (B) shows that at year
5, individual patients' difference from baseline eGFR varied from −80 to +59 mL/min/1.73 m2
TABLE 2 Glomerular filtration rate (GFR) category transition analysis during follow-up period
n Mean SD Min Max Median L-IQR U-IQR
GFR category at baseline
(mL/min/1.73m 2)
G1 (≥90) 2550 1.3 1.6 0 5 0 0 2
G2 (60-89) 3900 1.3 1.5 0 5 1 0 2
G3a (45-59) 962 2.6 1.7 0 5 3 1 4
G3b (30-44) 307 2.1 1.7 0 5 2 1 3
G4 (15-29) 47 2.9 1.9 0 5 3 1 5
G5 (<15) N/A N/A N/A N/A N/A N/A N/A N/A
All 7766 1.5 1.6 0 5 1 0 3
Abbreviations: eGFR, estimated glomerular filtration rate; L-IQR, lower interquartile range; max, maximum; min, minimum; SD, standard deviation; U-IQR,
upper interquartile range.
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known. However, there are some limitations to this analysis. The
study design may also have contributed to the increasing trend in
eGFR for patients in the lower category (G4), because five serum cre-
atinine measurements were required at yearly intervals following the
index measurement. This criterion was needed to ensure that patients
had enough data to allow sufficient follow-up, although it is possible
that this could have led to the exclusion of individuals with low renal
function who died over the study period thereby leaving a sample that
overrepresented the G4 patients whose renal function increased over
time. The majority of people were excluded because of a lack of
serum creatinine measurements during the follow-up period (82.9%;
32 358 out of 39 047 excluded patients), although analysis showed
that there were no relevant differences in the baseline characteristics
between included versus excluded individuals.
The CKD-EPI equation was used in the main analysis as it is the
method recommended by NICE for GFR estimation.19 NICE recom-
mend the CKD-EPI equation, as it is considered to be more accurate
than the MDRD Study equation at the population level, less biased at
a GFR of >60 mL/min/1.73 m2, and performs better in people aged
75 years and over.19 However, it has been found to lack precision at
the individual level.22,23 Therefore, we also performed a sensitivity
analysis using the MDRD equation to assess the robustness of the
results. This analysis showed similar overall trends to the main analy-
sis: a gradual decline in eGFR in the overall population with variation
at GFR category and individual patient level. It is also worth consider-
ing that most clinicians use estimated, not measured, GFR to manage
their patients, despite the limitations in providing patient-level preci-
sion. The methodology of this study is therefore reflective of that car-
ried out in clinical practice, thus the results should be applicable and
relevant to real-world management of patients, particularly in the UK.
As for all CPRD or database studies, the results are dependent on
the quality of the data entry. Ethnicity data, for example, are not well
recorded in CPRD. HES data were used to supplement the informa-
tion provided in CPRD, as ethnicity is required to calculate eGFR
according to the CKD-EPI equation. It is possible that use of HES data
could increase the proportion of patients with more severe disease or
complications than the general population, as these patients are more
likely to have an HES record than patients with milder disease. In the-
ory this could lead to a bias in the overall population. However, it
should not have a significant impact on the trends shown in GFR cate-
gories, or at the individual level. Another measure that is difficult to
assess in CPRD is quality of general practitioner or general practice,
and this may have an impact on renal function variation in people with
T2DM. This may also produce some bias in the results, as we are
unable to identify how the practices included in our study perform
against any clinical quality metrics. However, because all the practices
included met the “up-to-standard” metric, it is probable that each pos-
sessed a reasonable level of quality and were suitable for research.
Previous research, including observational studies and a random-
ized controlled trial, has shown that eGFR tends to decline over time
among patients with T2DM; some studies have found that groups of
patients may experience varying rates of renal function decline, with
some exhibiting rapid decline and others slower decline.6–14 The
observational studies, in particular, have also reported differences in
the rate of eGFR change based on certain patient characteristics
including age, ethnicity, positive or negative proteinuria at baseline
and hypertension.8-11 However, no recent studies have reported indi-
vidual patient-level variation in renal function in individuals with
T2DM. One previous UK study of eGFR change in people with T2DM
has used the CPRD database, although it only included people with
diagnoses or test results consistent with renal impairment.11 Similar to
our study, Cid Ruzafa et al. noted that individuals moved up and down
eGFR categories between baseline and end of follow-up.11 The inves-
tigators also modelled eGFR change as a continuous variable over
5.8 years, taking into account all observed eGFR values during the
study period. This showed an overall decrease in eGFR across the
whole population, a result that is comparable with the trend observed
in our study population. However, the model did not show any partic-
ular differences by GFR category, with all groups apart from G3a
showing a slow decline in renal function over time. Our analysis used
observational data to describe trends in eGFR over time and found
that eGFR change from baseline varies across different GFR catego-
ries. Our results also highlighted considerable differences in how renal
function changes over time at the individual level, which has not been
reported previously. Both studies show an overall decreasing trend in
renal function for people with T2DM, however, there are some differ-
ences in categories and individual patient level data between the ana-
lyses, which further highlights the complexity of managing these
patients in clinical practice. We also identified a large proportion of
the T2DM patient population who did not have yearly records of
serum creatinine measurements throughout the study period (that
was the reason for exclusion for 82.9% of excluded patients). This gap
between real-world practice and clinical guidelines does not help to
reduce the complexity of managing patients with T2DM. Rather, it
highlights the importance of a regular assessment of renal function in
people with T2DM, also in view of the level of variation in eGFR seen
in our study.
In conclusion, the results of this study show that, although the
overall population experienced a downward trend in their eGFR over
time, there was also considerable variation within clinical categories
of renal function and at the individual level, with patients' renal func-
tion increasing as well as decreasing over 5 years. This highlights the
difficulty when prescribing glucose-lowering therapies based on a sin-
gle measurement of renal function, as well as the importance of regu-
lar monitoring of renal function in people with T2DM.
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